Zydus Wellness (531335) Q4 03/04 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 03/04 earnings summary
3 Nov, 2026Executive summary
FY 2003-04 sales and other income rose to Rs 1,839.38 lakh from Rs 912.53 lakh; net profit increased to Rs 184.23 lakh from Rs 93.58 lakh.
Growth accompanied wider distribution and product additions across margarine, butter and processed cheese.
Financial highlights
Sales and other income increased 101.56% YoY to Rs 1,839.38 lakh; expenditure rose 98.74% to Rs 1,581.87 lakh.
Profit before tax was Rs 257.51 lakh versus Rs 116.57 lakh; profit after tax was Rs 184.23 lakh versus Rs 93.58 lakh.
Sales were Rs 1,801.24 lakh versus Rs 886.48 lakh; interest income was Rs 21.73 lakh versus Rs 12.95 lakh.
Proposed dividend was Rs 0.80 per Rs 10 share, absorbing Rs 44.93 lakh including dividend tax.
Outlook and guidance
Planned to expand margarine distribution into Madhya Pradesh, West Bengal and the North-East.
Planned to manufacture and market non-dairy whipping cream for bakeries, hotels and restaurants; the niche market was cited as growing ~30% annually.
Management intended to maintain focus on analogue and healthier food alternatives as health consciousness increased.
Latest events from Zydus Wellness
- Sales and EBITDA surged as gross margin expanded and brand growth continued.531335
Q2 26/27 - Sales rose, but FY98 ended with a Rs. 78.8 lakh net loss.531335
Q4 97/98 - Revenue rose 42%, profit after tax doubled, and a Rs. 0.60/share dividend was proposed.531335
Q4 02/03 - Sales surged, but FY99 ended with a Rs 45,36,571 loss before tax.531335
Q4 98/99 - Higher sales and production accompanied a narrower loss, but operating cash flow remained negative.531335
Q4 99/00 - FY02 profit improved as new-product investment positioned the business for growth.531335
Q4 01/02 - Revenue rose 60.75% as capacity expansion and regional growth plans advanced.531335
Q4 04/05 - Revenue surged 49%, but profit eased amid advertising investment; Nutralite Premium launched.531335
Q4 06/07 - Sales grew 9.12%, profit held near flat, and Cadila Healthcare took a 61.56% stake.531335
Q4 05/06